Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BR790 + tislelizumab
- Development stage
- Unknown
- Lead developer
- Shanghai Gopherwood Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
BR790 + tislelizumab is an investigational combination therapy being evaluated for the treatment of advanced solid tumors. Tislelizumab is a humanized IgG4 monoclonal antibody that targets programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor to restore antitumor immunity by blocking PD-L1 and PD-L2 from binding to PD-1 on T cells[3][6]. It is marketed under the brand name Tevimbra and was developed by BeiGene. BR790 is an orally administered small molecule; its precise mechanism of action has not been publicly disclosed as of April 2025, but it is being studied in combination with tislelizumab in early-phase clinical trials for safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary antitumor activity in patients with advanced solid tumors[5][7].
- Other names
- tislelizumabBR-790BR790BR 790
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on BR790 + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BR790 + tislelizumab.